Finerenone in Asian Patients with Type 2 Diabetes Mellitus and Albuminuric Chronic Kidney Disease: From Evidence to Implementation
Abstract
Finerenone reduces kidney and cardiovascular risk in patients with type 2 diabetes mellitus (T2DM) and albuminuric chronic kidney disease (CKD). Recent Asian subgroup, pooled, combination-therapy, Asian versus non-Asian, and real-world analyses have expanded the evidence base relevant to Asian practice. These data support the consistency of finerenone efficacy and safety in Asian patients and do not support withholding treatment on the basis of Asian ethnicity alone. However, the central question in Asia is shifting from whether finerenone is effective to how eligible patients can be identified, treated, monitored, and continued on therapy in routine care. This review summarizes Asian evidence from the FIDELIO-DKD, FIGARO-DKD, FIDELITY, and CONFIDENCE programs and emerging Asian real-world data. Focus is placed on persistent albuminuric risk, potassium monitoring, treatment sequencing with sodium-glucose cotransporter 2 inhibitors, and implementation feasibility across heterogeneous health-care systems. Finerenone should be considered an evidence-based add-on therapy when baseline potassium and kidney function are appropriate and early laboratory monitoring can be delivered. Simultaneous or early combination therapy may be appropriate in selected high-risk patients, but is not a universal default strategy. The practical priority is to strengthen CKD phenotyping, albuminuria testing, structured potassium monitoring, and care pathways that support sustained use of trial-proven…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.